| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| RNA | 2 | 2021 | 575 | 1.130 |
Why?
|
| Chemoradiotherapy | 3 | 2019 | 306 | 1.090 |
Why?
|
| Epigenesis, Genetic | 3 | 2021 | 500 | 1.040 |
Why?
|
| Esophageal Neoplasms | 3 | 2019 | 329 | 0.930 |
Why?
|
| RNA Processing, Post-Transcriptional | 2 | 2021 | 109 | 0.870 |
Why?
|
| Transcription, Genetic | 3 | 2021 | 1155 | 0.750 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2019 | 1093 | 0.680 |
Why?
|
| Methyltransferases | 1 | 2021 | 191 | 0.680 |
Why?
|
| Trans-Activators | 4 | 2013 | 443 | 0.670 |
Why?
|
| Esophagectomy | 2 | 2019 | 91 | 0.660 |
Why?
|
| Chromatin | 1 | 2021 | 394 | 0.630 |
Why?
|
| Neoadjuvant Therapy | 4 | 2019 | 358 | 0.630 |
Why?
|
| Adenocarcinoma | 2 | 2016 | 1184 | 0.610 |
Why?
|
| DNA-Binding Proteins | 5 | 2009 | 1238 | 0.600 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 611 | 0.580 |
Why?
|
| Kallikreins | 1 | 2016 | 49 | 0.550 |
Why?
|
| Lymph Nodes | 3 | 2024 | 546 | 0.520 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2018 | 2532 | 0.500 |
Why?
|
| Prostatic Neoplasms | 2 | 2016 | 1763 | 0.490 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2013 | 661 | 0.470 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2019 | 1349 | 0.470 |
Why?
|
| Prostate-Specific Antigen | 1 | 2016 | 358 | 0.470 |
Why?
|
| Fungal Proteins | 3 | 2004 | 141 | 0.460 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2017 | 351 | 0.450 |
Why?
|
| Rectal Neoplasms | 1 | 2014 | 127 | 0.450 |
Why?
|
| Circadian Rhythm | 1 | 2016 | 303 | 0.440 |
Why?
|
| Prostate | 1 | 2016 | 391 | 0.410 |
Why?
|
| Transcription Factors | 4 | 2010 | 1639 | 0.410 |
Why?
|
| Disease-Free Survival | 5 | 2019 | 1212 | 0.400 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 2402 | 0.390 |
Why?
|
| Aged | 16 | 2024 | 18878 | 0.380 |
Why?
|
| Histones | 1 | 2013 | 326 | 0.370 |
Why?
|
| Prognosis | 7 | 2024 | 3746 | 0.360 |
Why?
|
| Neoplasm Staging | 6 | 2019 | 1978 | 0.350 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2024 | 393 | 0.350 |
Why?
|
| Bone Marrow | 2 | 2022 | 442 | 0.350 |
Why?
|
| Middle Aged | 16 | 2024 | 25612 | 0.330 |
Why?
|
| Rhabdoid Tumor | 1 | 2008 | 19 | 0.310 |
Why?
|
| Brucella abortus | 2 | 2019 | 12 | 0.310 |
Why?
|
| Genome, Human | 1 | 2013 | 766 | 0.310 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2008 | 59 | 0.300 |
Why?
|
| Promoter Regions, Genetic | 4 | 2009 | 956 | 0.290 |
Why?
|
| Radiotherapy, Conformal | 1 | 2007 | 84 | 0.290 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 6704 | 0.280 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2021 | 782 | 0.270 |
Why?
|
| Biomarkers, Tumor | 3 | 2016 | 1519 | 0.270 |
Why?
|
| Mutation | 5 | 2024 | 4092 | 0.260 |
Why?
|
| Humans | 26 | 2024 | 88365 | 0.260 |
Why?
|
| Neoplasms | 1 | 2021 | 2995 | 0.260 |
Why?
|
| Cohort Studies | 4 | 2019 | 2833 | 0.250 |
Why?
|
| Adult | 14 | 2024 | 26266 | 0.250 |
Why?
|
| Neoplasms, Second Primary | 2 | 2020 | 258 | 0.240 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2004 | 61 | 0.240 |
Why?
|
| Treatment Outcome | 5 | 2024 | 8136 | 0.240 |
Why?
|
| Female | 18 | 2024 | 45621 | 0.240 |
Why?
|
| Indans | 1 | 2024 | 35 | 0.230 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2016 | 176 | 0.230 |
Why?
|
| Rectal Diseases | 1 | 2003 | 24 | 0.230 |
Why?
|
| Male | 14 | 2024 | 41896 | 0.230 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2008 | 432 | 0.230 |
Why?
|
| Transcriptional Activation | 1 | 2004 | 289 | 0.220 |
Why?
|
| Colectomy | 1 | 2024 | 168 | 0.220 |
Why?
|
| Genes, Fungal | 1 | 2002 | 58 | 0.220 |
Why?
|
| Rectum | 1 | 2003 | 148 | 0.210 |
Why?
|
| Brachytherapy | 1 | 2003 | 121 | 0.210 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2022 | 20 | 0.210 |
Why?
|
| TATA-Box Binding Protein | 1 | 2002 | 6 | 0.210 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2022 | 30 | 0.210 |
Why?
|
| Radiation Injuries | 1 | 2003 | 160 | 0.210 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 630 | 0.210 |
Why?
|
| Retrospective Studies | 7 | 2024 | 8852 | 0.210 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2004 | 282 | 0.200 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2024 | 408 | 0.200 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 577 | 0.190 |
Why?
|
| Oligonucleotides | 2 | 2002 | 92 | 0.190 |
Why?
|
| Naphthyridines | 1 | 2021 | 27 | 0.190 |
Why?
|
| RNA Editing | 1 | 2021 | 34 | 0.180 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2003 | 294 | 0.180 |
Why?
|
| Brucellosis | 2 | 2019 | 13 | 0.180 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2021 | 131 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 2 | 2019 | 573 | 0.180 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2017 | 294 | 0.180 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2020 | 138 | 0.170 |
Why?
|
| Survival Rate | 3 | 2014 | 1881 | 0.170 |
Why?
|
| Periplasmic Proteins | 1 | 2019 | 6 | 0.170 |
Why?
|
| O Antigens | 1 | 2019 | 12 | 0.170 |
Why?
|
| Leukemia, Myeloid | 1 | 2020 | 249 | 0.170 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2018 | 20 | 0.160 |
Why?
|
| Cell Wall | 1 | 2019 | 66 | 0.160 |
Why?
|
| Ipilimumab | 1 | 2018 | 61 | 0.160 |
Why?
|
| Virulence Factors | 1 | 2019 | 110 | 0.160 |
Why?
|
| Survival Analysis | 2 | 2019 | 1542 | 0.160 |
Why?
|
| Induction Chemotherapy | 1 | 2019 | 149 | 0.160 |
Why?
|
| Sp1 Transcription Factor | 1 | 1997 | 21 | 0.160 |
Why?
|
| Zinc Fingers | 1 | 1997 | 57 | 0.150 |
Why?
|
| DNA | 2 | 2021 | 1308 | 0.150 |
Why?
|
| Chromosome Deletion | 2 | 2020 | 229 | 0.150 |
Why?
|
| Parathyroid Neoplasms | 1 | 2017 | 57 | 0.150 |
Why?
|
| Colitis, Ulcerative | 1 | 2024 | 723 | 0.150 |
Why?
|
| Genes, APC | 1 | 2017 | 26 | 0.150 |
Why?
|
| Stem Cell Niche | 1 | 2017 | 22 | 0.150 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 102 | 0.140 |
Why?
|
| Cell Cycle | 1 | 2019 | 508 | 0.140 |
Why?
|
| Gene Expression Regulation | 2 | 2021 | 1972 | 0.140 |
Why?
|
| Brucella Vaccine | 1 | 2016 | 6 | 0.140 |
Why?
|
| Sigma Factor | 1 | 2016 | 23 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 861 | 0.140 |
Why?
|
| Bacteriophage M13 | 1 | 1996 | 9 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 602 | 0.140 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 858 | 0.140 |
Why?
|
| Wnt Signaling Pathway | 1 | 2017 | 96 | 0.140 |
Why?
|
| Lymphatic Metastasis | 2 | 2008 | 498 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 190 | 0.130 |
Why?
|
| Retinoids | 1 | 2015 | 18 | 0.130 |
Why?
|
| Cell Lineage | 2 | 2022 | 288 | 0.130 |
Why?
|
| Adenoma | 1 | 2017 | 242 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1710 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2016 | 235 | 0.130 |
Why?
|
| B-Lymphocytes | 2 | 2010 | 736 | 0.130 |
Why?
|
| Animals | 10 | 2021 | 27134 | 0.130 |
Why?
|
| Organoplatinum Compounds | 1 | 2014 | 96 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2024 | 1847 | 0.120 |
Why?
|
| Leucovorin | 1 | 2014 | 222 | 0.120 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1997 | 437 | 0.120 |
Why?
|
| Macrophages | 3 | 2019 | 572 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2019 | 2285 | 0.120 |
Why?
|
| Melanoma | 1 | 2018 | 462 | 0.120 |
Why?
|
| Orbital Neoplasms | 1 | 2013 | 17 | 0.110 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 325 | 0.110 |
Why?
|
| Bevacizumab | 1 | 2014 | 286 | 0.110 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 2974 | 0.110 |
Why?
|
| Sarcoma, Myeloid | 1 | 2013 | 15 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2013 | 65 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 157 | 0.110 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2013 | 111 | 0.110 |
Why?
|
| Binding, Competitive | 3 | 1997 | 146 | 0.110 |
Why?
|
| Fluorouracil | 1 | 2014 | 559 | 0.110 |
Why?
|
| Prostatectomy | 1 | 2016 | 476 | 0.110 |
Why?
|
| Base Sequence | 4 | 2006 | 2333 | 0.110 |
Why?
|
| Remission Induction | 1 | 2014 | 734 | 0.110 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 136 | 0.110 |
Why?
|
| Peptides | 1 | 1996 | 646 | 0.110 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 147 | 0.100 |
Why?
|
| Methylation | 1 | 2013 | 265 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 282 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2014 | 262 | 0.100 |
Why?
|
| Immunohistochemistry | 2 | 2022 | 1787 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2013 | 691 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 3655 | 0.090 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2010 | 46 | 0.090 |
Why?
|
| Ikaros Transcription Factor | 1 | 2009 | 25 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2004 | 565 | 0.090 |
Why?
|
| Mice | 7 | 2021 | 11685 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 956 | 0.080 |
Why?
|
| Premedication | 1 | 2008 | 57 | 0.080 |
Why?
|
| SMARCB1 Protein | 1 | 2008 | 13 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 774 | 0.080 |
Why?
|
| Radiation Dosage | 1 | 2008 | 226 | 0.070 |
Why?
|
| Axilla | 1 | 2007 | 102 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 1215 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 477 | 0.070 |
Why?
|
| Spleen | 2 | 2019 | 431 | 0.070 |
Why?
|
| Doxorubicin | 1 | 2007 | 298 | 0.070 |
Why?
|
| Paclitaxel | 1 | 2008 | 477 | 0.070 |
Why?
|
| Myosin-Light-Chain Kinase | 1 | 2006 | 41 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 2333 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 994 | 0.070 |
Why?
|
| Binding Sites | 3 | 2010 | 1112 | 0.060 |
Why?
|
| Molecular Sequence Data | 3 | 2006 | 3030 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2019 | 1083 | 0.060 |
Why?
|
| Young Adult | 3 | 2024 | 6179 | 0.060 |
Why?
|
| Yeasts | 1 | 2004 | 49 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 331 | 0.060 |
Why?
|
| Adolescent | 3 | 2024 | 9138 | 0.060 |
Why?
|
| Oxadiazoles | 1 | 2024 | 38 | 0.060 |
Why?
|
| Genes, Reporter | 1 | 2004 | 275 | 0.060 |
Why?
|
| Plasmids | 1 | 2004 | 292 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 1997 | 2063 | 0.060 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 89 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 699 | 0.050 |
Why?
|
| Radiotherapy Dosage | 1 | 2003 | 471 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 2530 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2008 | 3673 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2007 | 769 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2017 | 3194 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2021 | 305 | 0.050 |
Why?
|
| Interferon-gamma | 2 | 2016 | 450 | 0.050 |
Why?
|
| Genes, p53 | 1 | 2020 | 109 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2006 | 1511 | 0.040 |
Why?
|
| Stromal Cells | 1 | 2020 | 150 | 0.040 |
Why?
|
| Brucella ovis | 1 | 2019 | 1 | 0.040 |
Why?
|
| Microbial Viability | 1 | 2019 | 32 | 0.040 |
Why?
|
| Genes, Essential | 1 | 2019 | 20 | 0.040 |
Why?
|
| Histocytochemistry | 1 | 2019 | 130 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2017 | 1986 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2021 | 391 | 0.040 |
Why?
|
| Genes, Bacterial | 1 | 2019 | 198 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 245 | 0.040 |
Why?
|
| DNA, Fungal | 1 | 1997 | 58 | 0.040 |
Why?
|
| Peptide Library | 1 | 1997 | 84 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2019 | 341 | 0.040 |
Why?
|
| Pyrvinium Compounds | 1 | 2017 | 5 | 0.040 |
Why?
|
| Mice, 129 Strain | 1 | 2017 | 57 | 0.040 |
Why?
|
| Plasma Cells | 1 | 2017 | 81 | 0.040 |
Why?
|
| Japan | 1 | 2017 | 303 | 0.040 |
Why?
|
| Protein Folding | 1 | 2019 | 282 | 0.040 |
Why?
|
| Haploinsufficiency | 1 | 2017 | 63 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 448 | 0.040 |
Why?
|
| Capsid Proteins | 1 | 1996 | 32 | 0.030 |
Why?
|
| Child | 1 | 2008 | 7082 | 0.030 |
Why?
|
| Viral Fusion Proteins | 1 | 1996 | 10 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1996 | 127 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 1997 | 411 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 230 | 0.030 |
Why?
|
| Gene Library | 1 | 1996 | 133 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2019 | 884 | 0.030 |
Why?
|
| DNA, Single-Stranded | 1 | 1996 | 92 | 0.030 |
Why?
|
| Biomarkers | 1 | 2022 | 1754 | 0.030 |
Why?
|
| CD18 Antigens | 1 | 2015 | 22 | 0.030 |
Why?
|
| CD11b Antigen | 1 | 2015 | 36 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2006 | 3360 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 167 | 0.030 |
Why?
|
| beta Catenin | 1 | 2017 | 266 | 0.030 |
Why?
|
| Tretinoin | 1 | 2015 | 128 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2007 | 2332 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 466 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2015 | 425 | 0.030 |
Why?
|
| Enteropathy-Associated T-Cell Lymphoma | 1 | 2013 | 2 | 0.030 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2013 | 14 | 0.030 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2013 | 8 | 0.030 |
Why?
|
| Exophthalmos | 1 | 2013 | 5 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 813 | 0.030 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2013 | 29 | 0.030 |
Why?
|
| Diplopia | 1 | 2013 | 13 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2013 | 85 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 66 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 306 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2013 | 110 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2013 | 295 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2013 | 219 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2014 | 399 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2013 | 464 | 0.020 |
Why?
|
| United States | 1 | 2024 | 6867 | 0.020 |
Why?
|
| Immunity, Active | 1 | 2009 | 9 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 539 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1639 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 1587 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 697 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2009 | 305 | 0.020 |
Why?
|
| Enterocytes | 1 | 2006 | 18 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2006 | 65 | 0.020 |
Why?
|
| Caco-2 Cells | 1 | 2006 | 123 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2009 | 424 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2006 | 283 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2006 | 272 | 0.020 |
Why?
|
| Exons | 1 | 2006 | 452 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2006 | 464 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 2633 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2006 | 2873 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 2002 | 0.010 |
Why?
|